Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Topical Oxytetracycline-Polymyxin—Further Observations: Use of Powder Without Allergic Eczematous Reactions

Topical Oxytetracycline-Polymyxin—Further Observations: Use of Powder Without Allergic Eczematous... Abstract In 1959, I reported on the use of oxytetracycline hydrochloride (Terramycin)-polymyxin B sulfate powder* in 5,691 patients without significant allergic reactions.1 Since that report, I have had the opportunity to use this preparation on more than 5,500 additional patients with dermatological problems similar to those in the previous report. Summary Together with 5,691 cases in a previous report, the present series of 5,500 cases brings to over 11,000 the total number of patients treated by me with a powder containing 3.31% oxytetracycline hydrochloride and 0.144% polymyxin B sulfate in U.S.P. lactose. In not a single case has there been observed a definite instance of eczematous dermatitis from the topical use of oxytetracycline hydrochloride or of polymyxin B sulfate. Conclusion With the powder preparation studied, allergic eczematous dermatitis from the topical use of oxytetracycline hydrochloride or polymyxin B sulfate would seem to be virtually nonexistent.Sherwood W. Barefoot, M.D., 1030 References 1. Terramycin Topical Powder, Charles Pfizer & Company, Inc., Brooklyn 6. Ample supplies of this preparation were furnished by the manufacturer for this study. 2. Barefoot, S. W.: Oxytetracycline Hydrochloride-Polymyxin B Sulfate Topical Powder , A.M.A. Arch. Derm. 79:455-457 ( (April) ) 1959.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Topical Oxytetracycline-Polymyxin—Further Observations: Use of Powder Without Allergic Eczematous Reactions

Archives of Dermatology , Volume 86 (2) – Aug 1, 1962

Topical Oxytetracycline-Polymyxin—Further Observations: Use of Powder Without Allergic Eczematous Reactions

Abstract

Abstract In 1959, I reported on the use of oxytetracycline hydrochloride (Terramycin)-polymyxin B sulfate powder* in 5,691 patients without significant allergic reactions.1 Since that report, I have had the opportunity to use this preparation on more than 5,500 additional patients with dermatological problems similar to those in the previous report. Summary Together with 5,691 cases in a previous report, the present series of 5,500 cases brings to over 11,000 the total number of patients...
Loading next page...
 
/lp/american-medical-association/topical-oxytetracycline-polymyxin-further-observations-use-of-powder-zygqpxuQDS
Publisher
American Medical Association
Copyright
Copyright © 1962 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1962.01590080106018
Publisher site
See Article on Publisher Site

Abstract

Abstract In 1959, I reported on the use of oxytetracycline hydrochloride (Terramycin)-polymyxin B sulfate powder* in 5,691 patients without significant allergic reactions.1 Since that report, I have had the opportunity to use this preparation on more than 5,500 additional patients with dermatological problems similar to those in the previous report. Summary Together with 5,691 cases in a previous report, the present series of 5,500 cases brings to over 11,000 the total number of patients treated by me with a powder containing 3.31% oxytetracycline hydrochloride and 0.144% polymyxin B sulfate in U.S.P. lactose. In not a single case has there been observed a definite instance of eczematous dermatitis from the topical use of oxytetracycline hydrochloride or of polymyxin B sulfate. Conclusion With the powder preparation studied, allergic eczematous dermatitis from the topical use of oxytetracycline hydrochloride or polymyxin B sulfate would seem to be virtually nonexistent.Sherwood W. Barefoot, M.D., 1030 References 1. Terramycin Topical Powder, Charles Pfizer & Company, Inc., Brooklyn 6. Ample supplies of this preparation were furnished by the manufacturer for this study. 2. Barefoot, S. W.: Oxytetracycline Hydrochloride-Polymyxin B Sulfate Topical Powder , A.M.A. Arch. Derm. 79:455-457 ( (April) ) 1959.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: Aug 1, 1962

References